<DOC>
	<DOCNO>NCT00120757</DOCNO>
	<brief_summary>Osteopenia osteoporosis describe frequently people HIV infection . This study test efficacy alendronate comparison placebo 2 year , people primary osteoporosis . People receive recommend adequate intake calcium vitamin D .</brief_summary>
	<brief_title>Efficacy Alendronate Versus Placebo Treatment HIV-associated Osteoporosis ( ANRS120 )</brief_title>
	<detailed_description>The purpose trial : - To study efficacy alendronate HIV-associated osteoporosis - To measure prevalence osteoporosis HIV patient detect risk factor large cohort HIV patient screen phase</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Nonpregnant Non menopausal woman Total femur BMD 2.5 SD ( T score ) lumbar spine BMD 2.5 SD ( T score ) BMD 1 associate vertebral osteoporotic fracture ( diminution vertebral height 20 % ) HIV infection know least 5 year CD4 cell count 50/mm3 Karnofsky score equal 70 Written informed consent . Osteoporosis result cause HIV : vitamin D deficiency ( case , receive highdose calcium vitamin D 1 month , patient randomize without new screening ) , renal failure , heart failure ( NHYA class III IV ) , treatment glucocorticoid dose equal 0.5mg/kg/d 15 day time inclusion previous 6 month ; thyroid endocrine disease untreated 6 month ; hypercalciuria Testosterone normal treatment hormonal BMI equal 18 Severe lung failure Chronic alcohol intoxication Ongoing opportunistic infection Gastric ulcer disease interfere oesophageal motility previous 3 month History treatment osteoporosis History malignancy previous 5 year ( except skin cancer Kaposi ) Cytotoxic chemotherapy cytokine therapy Liver cirrhosis Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Osteoporosis</keyword>
</DOC>